戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ian's choice (TPC; paclitaxel, docetaxel, or vinflunine).
2 otin or chemotherapy (docetaxel, paclitaxel, vinflunine).
3 igator's choice of paclitaxel, docetaxel, or vinflunine.
4 1200 mg or chemotherapy (physician's choice: vinflunine 320 mg/m(2), paclitaxel 175 mg/m(2), or 75 mg
5                                              Vinflunine 320 mg/m2 by 10-minute intravenous infusion w
6  at the mitotic IC(50) value was highest for vinflunine (4.2 +/- 0.2 microM), intermediate for vinore
7 study reports the clinical efficacy data for vinflunine, a novel microtubule inhibitor, in MPM.
8                                              Vinflunine, a novel vinca alkaloid, showed some activity
9 -generation Vinca alkaloids, vinorelbine and vinflunine, affect microtubule dynamics very differently
10  Thus the unique constellation of effects of vinflunine and vinorelbine on dynamic instability and tr
11                         The major effects of vinflunine and vinorelbine on dynamic instability were a
12         Here we have analyzed the effects of vinflunine and vinorelbine on microtubule dynamic instab
13 latively less powerful inhibitory effects of vinflunine and vinorelbine on microtubule dynamics bette
14                                 In addition, vinflunine and vinorelbine suppressed treadmilling, but
15 ifluoro-3',4'-dihydrovinorelbine (F12158, or vinflunine) and the parent compound, vinorelbine.
16                                              Vinflunine can be delivered with high-dose intensity in
17 axation times for polymer redistribution for vinflunine consistent with induction of the shortest spi
18                                              Vinflunine demonstrates 3-16-fold lower overall affinity
19 ntation velocity to compare vinorelbine- and vinflunine-induced self-association of porcine brain tub
20                                              Vinflunine is a novel Vinca alkaloid presently in Phase
21 ovides the only direct evidence to date that vinflunine is a tubulin-binding drug.
22 entirely consistent with our hypothesis that vinflunine is likely to result in reduced clinical neuro
23 eservoir(s) may be partially responsible for vinflunine's high efficacy and minimal side effects.
24                      These data suggest that vinflunine should be further evaluated in the management
25 shortening in vitro, whereas vinorelbine and vinflunine suppress the rate and extent of microtubule g
26 or inhibition of HeLa cell proliferation for vinflunine, vinorelbine, and vinblastine were 18, 1.25,
27 ng immune cells [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), an